Navigation Links
BioCryst Reports Fourth Quarter and Full Year 2009 Financial Results and Provides Corporate Update
Date:2/4/2010

ase 2 study for forodesine in the treatment of cutaneous T-cell lymphoma (CTCL) achieved its protocol-specified objective of enrolling 100 late-stage patients (Stage IIB to IVA).  The Company expects to report data from the study in the second half of 2010.
  • The Phase 2 single-arm, open-label study evaluating 200 mg of forodesine twice-daily in patients with chronic lymphocytic leukemia (CLL) is beyond half way to its enrollment target of 26 patients and is ongoing.

BCX4208 Program

  • During the fourth quarter 2009, BioCryst began enrolling a randomized, double-blind, placebo-controlled Phase 2 study to evaluate the efficacy and safety of BCX4208 in subjects with gout.  The study's primary objective is to determine the effect of different doses of orally administered BCX4208 on serum uric acid levels in patients with gout.  Results from the first part of this study are expected in the second quarter of 2010.  

  • BioCryst is evaluating alternatives for an additional blinded study to evaluate the efficacy and safety of BCX4208 as an add-on treatment with another urate-lowering treatment for gout that has a different mechanism of action.

Conference Call and Web Cast

BioCryst's management team will host a conference call and Web cast on Thursday, February 4, 2010 at 11:00 a.m. Eastern Time to discuss these financial results and recent corporate developments.  To participate in the conference call, please dial 1-888-206-4913 (United States) or 1-913-312-9315 (International).  No passcode is needed for the call.  The Web cast can be accessed by logging onto

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. BioCrysts Partner Shionogi Launches Peramivir In Japan Under The Name RAPIACTA
2. BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors
3. BioCryst Announces Pricing of Public Offering of Common Stock
4. BioCryst to Present at Oppenheimer Healthcare Conference
5. Emergency Use Authorization Granted For BioCrysts Peramivir
6. BioCryst to Present at JMP Securities Healthcare Conference
7. BioCryst Clarifies Government Declaration Regarding Peramivir
8. BioCryst Provides Update Regarding Peramivir for Influenza
9. BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza
10. BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
11. BioCryst Pharmaceuticals to Announce Peramivir Update and First Quarter 2009 Financial Results on May 8, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014  Australian drug delivery ... that it has raised A$19.3 million via a placement ... Europe , the U.S., Asia ... million from a share purchase plan (SPP) to be ... will be made in two tranches. "This ...
(Date:7/11/2014)... , July 11, 2014  Veran Medical ... announced today the positive, cost-effective final results ... SPiNPerc™ procedure. The SPiNPerc endobronchial percutaneous biopsy ... percutaneous approach to biopsy when a traditional ... and physicians experience positive financial outcomes when ...
(Date:7/10/2014)... NEWS, Virginia , 11. Juli ... Hersteller von Kameras für die molekulare ... (MBI/BSGI), hat heute die CE-Zulassung für ... dem CE-Zeichen kann Dilon das Produkt ... Vertriebsbereich auf den Großteil der europäischen ...
Breaking Medicine Technology:Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Veran Medical Publishes Lung Cancer Patient Management Study 2Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2
... , Part of International Internet Week ... The U.S. Food and Drug Administration today completed ... Week of Action (IIWA), intended to curb illegal actions ... During the effort, the FDA,s Office of Criminal Investigations ...
... , Primary Care Doctors, Endocrinologists Feel ... N.J., Nov. 19 Nearly one-third of doctors surveyed said ... sufficient reimbursement to provide comprehensive care to their patients with ... and primary care doctors published today in American Health ...
Cached Medicine Technology:UPDATE: FDA Issues 22 Warning Letters to Web site Operators 2Doctors Cite Time, Low Reimbursement As Barriers To Providing Comprehensive Diabetes Care, Survey Results Show 2Doctors Cite Time, Low Reimbursement As Barriers To Providing Comprehensive Diabetes Care, Survey Results Show 3Doctors Cite Time, Low Reimbursement As Barriers To Providing Comprehensive Diabetes Care, Survey Results Show 4Doctors Cite Time, Low Reimbursement As Barriers To Providing Comprehensive Diabetes Care, Survey Results Show 5
(Date:7/11/2014)... The report “Probiotics Market by ... Feed), Applications (Regular, Therapeutic, Preventive Health Care) & ... Forecasts to 2019 ” defines and segments the ... of the market value of probiotic products and ... restraining factors for the global market with an ...
(Date:7/11/2014)... Global enterprises today are shifting towards the changing trend ... services offer these global enterprises a strategic method to ... rising operational costs to companies. The aim to minimize ... global market driver for expanding the managed services market ... is estimated to grow from $142.75 billion in 2013 ...
(Date:7/11/2014)... Toledo, Ohio (PRWEB) July 11, 2014 ... (Morgenson 7/10/14) and FiercePharma (Weintraub 7/11/14), a significant number ... in blood sugar, abdominal issues and even death from ... exposed. , According to the Times report , ... events in 2013 reported by patients was almost 14% ...
(Date:7/11/2014)... its kind has found that organic foods and ... conventional counterparts, including more antioxidants and fewer, less ... an unprecedented 343 peer-reviewed publications comparing the nutritional ... foods, including fruits, vegetables, and grains. The study ... between organic and non-organic foods. , "Science ...
(Date:7/11/2014)... HealthDay Reporter THURSDAY, July 10, 2014 ... the worldwide scourge of dengue fever was somewhat successful in ... prevented dengue fever in 56 percent of the 10,000 kids ... more than 88 percent of them from severe disease. In ... sometimes death. "This vaccine has already proven to be ...
Breaking Medicine News(10 mins):Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 3Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 4Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 5Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:Acthar’s Deadly Adverse Events Revealed 2Health News:Acthar’s Deadly Adverse Events Revealed 3Health News:Major study documents nutritional and food safety benefits of organic farming 2Health News:Major study documents nutritional and food safety benefits of organic farming 3Health News:Dengue Fever Vaccine Shows Some Promise in Trial 2Health News:Dengue Fever Vaccine Shows Some Promise in Trial 3
... 1 (HealthDay News) -- Increasing daily soluble fiber intake may ... other substances linked to a host of chronic diseases, according ... found just under the skin, visceral fat is located deep ... Researchers at Wake Forest Baptist Medical Center found the way ...
... believe medical practitioners can help reduce the number of ... effectively educating their patients about the importance of mammography ... the Journal of Cancer Education , Rosalie Young, ... and Jason Booza, Ph. D., assistant professor, all from ...
... Researchers from the University of Leeds will carry out a ... or treat the spread of bowel cancer to the liver. ... of pure Eicosapentaenoic Acid (EPA) - a naturally occurring omega-3 ... oil preparations in health stores and supermarkets nationwide. Gastroenterologist ...
... (MGH) researchers have discovered the first of an entirely ... with the development of blood vessels. In a report ... /Early Edition, the investigators describe how a compound derived ... novel mechanism, to interfere with blood vessel formation in ...
... The Obama administration turned a bright spotlight on prescription ... Drug Control Policy released a national action plan and ... cover article in the July edition of the ... focus that spotlight on themselves both as major sources ...
... Bill Keevil, Head of the Microbiology Group and ... University of Southampton, has presented research into the ... on antibiotic-resistant organisms at the World Health Organization,s ... (ICPIC). ,New Insights into the Antimicrobial Mechanisms ...
Cached Medicine News:Health News:Soluble Fiber Appears Key to Trimming 'Bad Fat' 2Health News:Health providers should emphasize breast cancer screening, Wayne State University research finds 2Health News:Leeds researchers test benefit of fish oil in bowel cancer spread 2Health News:Mass. General team identifies new class of antiangiogenesis drugs 2Health News:Research examines dentists' role in painkiller abuse 2Health News:Research examines dentists' role in painkiller abuse 3Health News:Copper reduces infection risk by more than 40 percent 2
... offers the comfort of a surgical microscope ... The microscope offers brilliant resolution, large depth ... color reproduction. A separate prism for optimum ... with a special jalousie diaphragm. It offers ...
... surgical magnifying loupes are quality surgical ... which provide the healthcare professional a ... depth of field. Each set of ... fully lined wooden box and includes ...
... field-of-view enables high-quality full-coverage body imaging. New ... architecture. New powerful Quasar Dual gradients designed ... to 80 mT/m SR 200. New ... exploit the power of 3.0T in a ...
GE's Signa Contour/i system uses the latest innovations from around the world to bring new standards in quality and value to MRI....
Medicine Products: